Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement.
Multiple myeloma is a neoplastic plasma cell dyscrasia that on a yearly basis affects nearly 17,000 individuals and kills more than 11,000. Although no cure exists, many effective treatments are available that prolong survival and improve the quality of life of patients with this disease. The purpose of this consensus is to offer a simplified, evidence-based algorithm of decision making for patients with newly diagnosed myeloma. In cases in which evidence is lacking, our team of 18 Mayo Clinic myeloma experts reached a consensus on what therapy could generally be recommended. The focal point of our strategy revolves around risk stratification. Although a multitude of risk factors have been identified throughout the years, including age, tumor burden, renal function, lactate dehydrogenase, beta2-microglobulin, and serum albumin, our group has now recognized and endorsed a genetic stratification and patient functional status for treatment.
Dispenzieri
Angela
A
Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA. dispenzieri.angela@mayo.edu
Rajkumar
S Vincent
SV
Gertz
Morie A
MA
Fonseca
Rafael
R
Lacy
Martha Q
MQ
Bergsagel
P Leif
PL
Kyle
Robert A
RA
Greipp
Philip R
PR
Witzig
Thomas E
TE
Reeder
Craig B
CB
Lust
John A
JA
Russell
Stephen J
SJ
Hayman
Suzanne R
SR
Roy
Vivek
V
Kumar
Shaji
S
Zeldenrust
Steven R
SR
Dalton
Robert J
RJ
Stewart
A Keith
AK
D000465:Algorithms; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003657:Decision Making; D019317:Evidence-Based Medicine; D006801:Humans; D009101:Multiple Myeloma / Q000235:genetics / Q000628:therapy*; D010166:Palliative Care; D012307:Risk Factors; D033581:Stem Cell Transplantation
D000970:Antineoplastic Agents